Back to search

Article

Evaluation of the Effect of Sofosbuvir and Daclatasvir in Hospitalised COVID-19 Patients: A Randomized Double-Blind Clinical Trial (DISCOVER)

2021-02-25

Abstract excerpt

Background: The combination of sofosbuvir (SOF) and daclatasvir (DCV) has shown preliminary efficacy for patients with COVID-19 in five open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir and daclatasvir to standard care improved clinical endpoints in hospitalized patients with moderate or severe COVID-19. <br><br>Methods: This was a placebo-controlled, ran...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b16ec875-d58e-5932-93f6-0de323fbd2ee
DOI
10.2139/ssrn.3792895
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Evaluation of the Effect of Sofosbuvir and Daclatasvir in Hospitalised COVID-19 Patients: A Randomized Double-Blind Clinical Trial (DISCOVER)DOI 10.2139/ssrn.3792895
Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials.Semantic proximity
Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial.Semantic proximity
The Saudi Critical Care Society Practice Guidelines on the Management of COVID-19 in the ICU: Therapy SectionSemantic proximity
Analysing COVID treatment outcomes in dedicated wards at a large university hospital in northern Poland. A result-based observational studySemantic proximity
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.Semantic proximity
REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity
Outcomes evaluated in controlled clinical trials on the management of COVID-19: A methodological systematic reviewSemantic proximity
A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial.Semantic proximity
Favipiravir and/or Nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 (FANTAZE).Semantic proximity
Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.Semantic proximity
On whether therapeutic plasma exchange is an effective cure against severe/critical COVID-19 pneumoniaSemantic proximity
The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trialsSemantic proximity
Select a neighboring publication to make it the new centre.